ondansetron
ondansetron.JPG

CLINICAL USE

Anti-emetic

DOSE IN NORMAL RENAL FUNCTION

Oral: 4–24 mg daily in 2–3 divided dosesIV: 8–32 mg dailyPR: 16 mg pre-chemotherapy

PHARMACOKINETICS

  • Molecular weight                           :293.4
  • %Protein binding                           :70–76
  • %Excreted unchanged in urine     : <5
  • Volume of distribution (L/kg)       :2
  • half-life – normal/ESRD (hrs)      :3–6/5.4

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Unlikely to be dialysed. Dose as in normal renal function
  • HD                     :Not dialysed. Dose as in normal renal function
  • HDF/high flux   :Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD      :Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • None known

    ADMINISTRATION

    Reconstition

    Route

    Oral, IV, IM, rectal

    Rate of Administration

    IV bolus over 3–5 minutes

    IV infusion

    : over 15 minutes Continuous infusion: 1 mg/hour

    Comments

    Dilute in 50–100 mL of sodium chloride 0.9% or glucose 5%

    OTHER INFORMATION

    Can be used to treat uraemic pruritus Renal clearance of ondansetron is low



    See how to identify renal failure stages according to GFR calculation

    See how to diagnose irreversible renal disease

    Home

  • other drugs